Brief: GeNeuro Presents Phase 2B Data Demonstrating Neuroprotective Effect Of GNbAC1 In Multiple Sclerosis Patients
15/10/2018 06:40
Oct 15 (Reuters) - GENEURO SA GNRO.PA :
* GENEURO PRESENTS PHASE 2B DATA DEMONSTRATING NEUROPROTECTIVE EFFECT OF GNBAC1 IN MULTIPLE
SCLEROSIS PATIENTS AT ECTRIMS 2018
* CONFIRMATION OF SAFETY AND TOLERABILITY
* NEUROPROTECTIVE EFFECTS ALSO SEEN IN NON-ACTIVE MS PATIENTS
* POSITIVE EFFECTS OBSERVED ON KEY NEUROPROTECTION ENDPOINTS RELATED TO MS DISEASE
PROGRESSION
Source text for Eikon: ID:nBw38jK0xa
Further company coverage: GNRO.PA
(Gdynia Newsroom)
((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Geneuro SA
See all newsBrief: Geneuro SA Postpones Publication Of Half-Yearly Financial Report
Brief: Geneuro SA Announces Extension Of Its Definitive Debt-Restructuring Moratorium
Brief: Geneuro SA Announces The Opening Of Receivership Proceedings For Its French Subsidiary Geneuro Innovation Sas
Brief: Geneuro Confirms Top-Line Results In Its Post-Covid Trial By End-June
Brief: Geneuro announces EUR 5 Mln private placement